NuvOx Pharma is focused on developing innovative oxygen therapeutics aimed at reversing hypoxia, a condition where cells do not receive sufficient oxygen, which is critical in various life-threatening diseases. Their lead product, NanO₂, is designed to enhance the transport of oxygen from the lungs to the bloodstream and subsequently to tissues. The company has conducted over 30 animal studies demonstrating the therapeutic effects of NanO₂ across seven different medical indications. Currently, NuvOx is advancing its clinical trials, including a Phase IIb trial for glioblastoma patients and a Phase Ib trial for acute hypoxemic respiratory failure, with support from various funding bodies.

The technology behind NanO₂ is rooted in the pioneering work of Dr. Evan Unger, who previously developed a successful microbubble product for ultrasound imaging. NuvOx's approach utilizes a novel class of perfluorocarbon emulsions, specifically dodecafluoropentane (DDFPe), which has been shown to be a more effective oxygen carrier than earlier generations of perfluorocarbon emulsions. This unique formulation allows for improved oxygen delivery at significantly lower doses, representing a new paradigm in oxygen therapeutics. The ongoing research and clinical trials underscore NuvOx's commitment to advancing treatments that can significantly impact patient outcomes in conditions associated with hypoxia.

United States

NuvOx Pharma is a biotechnology company based in Tucson, Arizona that is developing a first-in-class oxygen therapeutic to treat life-threatening diseases where hypoxia plays a role. Over 30 animal studies have shown therapeutic effect in seven different indications. Phase Ib/II clinical trials in stroke and oncology demonstrated safety and evidence of efficacy, and the company is preparing to run a Phase IIa trial in COVID-19 patients with Acute Hypoxemic Respiratory Failure (AHRF).

Cardiovascular Diseases

Central Nervous System (CNS)

Genetic Diseases

Hematologic Diseases

Infectious Diseases

Nervous System Diseases

Pathological Conditions

NuvOx Pharma

Stroke

Drug #1 (NanO2)

COVID-19

Hypoxemia

Drug #2 (NanO2)

Hemorrhagic Shock

Myocardial infarction

Sickle cell disease

Traumatic brain injury

Drug #3 (NanO2)

Arizona

Small Molecule Pharmaceuticals

Therapeutic

NuvOx Pharma

Company Details